Study of GemOx and Vandetanib in Advanced Solid Malignancy

Vandetanib is a pill that will be self-administered orally on Days 1-14 of each 14-day cycle. The dose of vandetanib each subject will receive will be determined by a dose escalation schedule (either 200 mg or 300 mg per day), which will be followed to determine the MTD of the study drug combination (vandetanib + GemOx). In the absence of disease progression, unacceptable toxicities, or other complications, the vandetanib and GemOx combination may continue per protocol for a maximum of 6 cycles, or 12 weeks. In subjects who show response or stable disease, vandetanib may be continued as a single agent beyond the 6 cycle maximum, at the investigator's discretion.

30-minute IV infusion of 1000 mg/m\^2 gemcitabine on Day 1 of each 14-day cycle.

Immediately following gemcitabine IV: 2-hour IV infusion of 85 mg/m\^2 oxaliplatin on Day 1 of each 14-day cycle.